Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Phys Vivaspharmacological

Phys Vivas · pharmacological

Cardiac Glycoside — Viva Defence

DCE viva defence for Cardiac Glycoside.

1 min readVerification in progress

Target exams

FRACP DCEMRCP PACES
On this page
Study tools

Target exams

FRACP DCEMRCP PACES
Prompt
DCE viva defence for Cardiac Glycoside.

Cardiac Glycoside Viva

Long Case Viva Defence

Opening statement

"This patient presents with a problem best framed as Cardiac Glycoside. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]

Examiner questions

Q1: "What makes this urgent?" [1]

"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]

Q2: "What is your first investigation package?" [2]

"I order tests that change management now, not a scattergun panel." [1] [2]

Q3: "Walk me through treatment." [1]

"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]

Q4: "What is the classic trap?" [2]

"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]

Physician Medicine Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Physician Medicine fellowship library.

Sign in to continueSee pricing
References6ShowHide
  1. [1]Kumar A, Ul Haque Z, Rai A Evaluation of the Therapeutic Potential and Safety of Terminalia arjuna in Heart Failure Management: A Systematic Review and Meta-analysis of Randomized Controlled Trials Ann Afr Med, 2026.PMID 42389976
  2. [2]Ecker PAM, Schaper A, Bräunig HJ, Seifert R Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin Eur J Clin Pharmacol, 2026.PMID 42334625
  3. [3]Kotecha D, Bunting KV, Gill SK, et al. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial JAMA, 2020.PMID 33351042
  4. [4]Mehra MR, Vukicevic M, Desai AS Digitalis Today: From Doctrine to Disrepute to Disciplined Reconsideration J Card Fail, 2026.PMID 42331138
  5. [5]Bavendiek U, Bauersachs J [Digitalis and Heart Failure] Dtsch Med Wochenschr, 2026.PMID 42214363
  6. [6]Jerical C, Ahmed E, Asifa S, Ariba S, et al. Therapeutic Impact of Cardiac Glycosides (Digoxin and Digitoxin) in Heart Failure With Reduced Ejection Fraction: A Systematic Review Cardiol Rev, 2026.PMID 42132739
Physician Medicine Pro

$29/ monthor $279 / year

The complete Physician Medicine library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousBeta Blocker and Calcium Channel Blocker Toxicity — Viva DefencepharmacologicalNextIron Toxicity — Viva Defencepharmacological